Peripheral T-cell lymphoma: From biology to practice to the future

医学 外周T细胞淋巴瘤 淋巴瘤 外围设备 计算生物学 癌症研究 免疫学 内科学 T细胞 免疫系统 生物
作者
Owen A. O’Connor,Helen Ma,Jason Yongsheng Chan,Seok Jin Kim,Sang Eun Yoon,Won Seog Kim
出处
期刊:Cancer Treatment Reviews [Elsevier]
卷期号:: 102793-102793
标识
DOI:10.1016/j.ctrv.2024.102793
摘要

Recent advancements in comprehending peripheral T-cell lymphomas (PTCLs) validate and broaden our perspective, highlighting their diverse nature and the varying molecular mechanisms underlying the entities. Based on a comprehensive accumulated understanding, the PTCLs currently overcome the most challenging features of any disease: rarity, incredible heterogeneity, and a lack of any established standard of care. The treatments deployed in the front-line are extrapolated from regimens developed for other diseases. The recent approval of the three drugs brentuximab vedotin (BV), pralatrexate, and belinostat for patients with relapsed or refractory disease has provided clues about pathophysiology and future directions, though challenges satisfying post-marketing requirements (PMR) for those accelerated approvals have led to one of those drugs being withdrawn and put the other two in jeopardy. Edits of the front-line regimens, often called CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)-plus approaches, look more like CHOP-minus strategies, as the toxicity of five-drug regimens often reduces the dose intensity of the added 'novel' drug, nullifying any hope of an advance. The turmoil in the field produced by the aforementioned, coupled with an ever-changing classification, has left the field uncertain about the path forward. Despite these challenges, empiric findings from studies of novel drug approaches, coupled with a logic emerging from studies of PTCL lymphomagenesis, have begun to illuminate, albeit faintly for some, a potential direction. The empiric finding that drugs targeting the discrete components of the PTCL epigenome, coupled with the description of multiple mutations in genes that govern epigenetic biology, offers, at the very least, an opportunity to finally be hypothesis-driven. The most recent recognition that the only combination of drugs shown to markedly improve progression-free survival (PFS) in patients with relapsed disease is one based on dual targeting of different and discrete components of that epigenetic biology has established a possibility that circumnavigating chemotherapy addition studies is both plausible, feasible, and likely the best prospect for a quantum advance in this disease. Herein, we analyze PTCL through a 2025 lens, highlighting and underscoring walls that have impeded progress. We will critically explore all the clues and the panoramic view of PTCL research.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
lamborghini193完成签到,获得积分10
4秒前
匆匆赶路人完成签到 ,获得积分10
4秒前
6秒前
属实有点拉胯完成签到 ,获得积分10
12秒前
zwzxtx完成签到 ,获得积分10
15秒前
虚幻元风完成签到 ,获得积分10
17秒前
木又完成签到 ,获得积分10
20秒前
皮卡丘完成签到,获得积分10
29秒前
卡卡完成签到,获得积分10
33秒前
33秒前
34秒前
淡淡妙竹完成签到 ,获得积分10
34秒前
笨笨忘幽完成签到,获得积分10
37秒前
干净以珊发布了新的文献求助10
39秒前
天才小能喵完成签到 ,获得积分0
44秒前
领导范儿应助干净以珊采纳,获得10
46秒前
49秒前
tyl完成签到 ,获得积分10
50秒前
CLTTT完成签到,获得积分10
50秒前
有机发布了新的文献求助10
54秒前
干净以珊完成签到,获得积分20
54秒前
1分钟前
钟声完成签到,获得积分0
1分钟前
dent强完成签到 ,获得积分10
1分钟前
任性星星完成签到 ,获得积分10
1分钟前
开放访天完成签到 ,获得积分10
1分钟前
1分钟前
Xie完成签到 ,获得积分10
1分钟前
优雅的凝阳完成签到 ,获得积分10
1分钟前
LT完成签到 ,获得积分10
1分钟前
1分钟前
神勇的天问完成签到 ,获得积分10
1分钟前
阳炎完成签到,获得积分10
1分钟前
老王家的二姑娘完成签到 ,获得积分10
1分钟前
hua完成签到 ,获得积分10
2分钟前
黄花菜完成签到 ,获得积分10
2分钟前
Hey完成签到 ,获得积分10
2分钟前
2分钟前
Hiaoliem完成签到 ,获得积分10
2分钟前
小墨墨完成签到 ,获得积分10
2分钟前
高分求助中
Evolution 10000
Distribution Dependent Stochastic Differential Equations 500
A new species of Coccus (Homoptera: Coccoidea) from Malawi 500
A new species of Velataspis (Hemiptera Coccoidea Diaspididae) from tea in Assam 500
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 500
Die Gottesanbeterin: Mantis religiosa: 656 400
Mantiden: Faszinierende Lauerjäger Faszinierende Lauerjäger 400
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3158663
求助须知:如何正确求助?哪些是违规求助? 2809828
关于积分的说明 7883769
捐赠科研通 2468539
什么是DOI,文献DOI怎么找? 1314323
科研通“疑难数据库(出版商)”最低求助积分说明 630582
版权声明 601983